Advances in the Biologic Role of HER2 in Metastatic Breast Cancer
Chapter 3Hope S. Rugo, MD, Claudine Isaacs, MD, and William J. Gradishar, MD, discuss the most exciting advances in the biologic role of HER2 in metastatic breast cancer.
HER2+ Metastatic Breast Cancer: Insights from the Lab and Clinic
Joyce O’Shaughnessy, MD, and Hope S. Rugo, MD, discuss recent treatment advances for patients with HER2+ metastatic breast cancer.
Trastuzumab Resistance in Metastatic Breast Cancer
Joyce O’Shaughnessy, MD, and Hope S. Rugo, MD, discuss strategies for overcoming trastuzumab resistance in patients with breast cancer.
Strategies in the Management of HER2+ Metastatic Breast Cancer
Hope S. Rugo, MD, and Joyce O’Shaughnessy, MD, review the current recommendations for the management of metastatic HER2 positive breast cancer.
First-Line Treatment With a Lapatinib-Based Regimen
Hope S. Rugo, MD, and Joyce O’Shaughnessy, MD, discuss the use of lapatinib as a first-line treatment option.
Strategies for Overcoming Trastuzumab Resistance
Hope S. Rugo, MD, and Joyce O’Shaughnessy, MD, discuss practical strategies for treating patients who experience resistance to trastuzumab treatment.
New Anti-HER2 Agents or Targets for Metastatic Breast Cancer
Joyce O’Shaughnessy, MD, and William J. Gradishar, MD, review upcoming research regarding anti-HER2 agents for patients with metastatic breast cancer.
HER2-Targeted Therapies in the Neoadjuvant Treatment Setting
William J. Gradishar, MD, discusses the current status of U.S. Food and Drug Administration approvals for HER2-targeted therapies for patients receiving neoadjuvant therapy.
Lapatinib and the Neoadjuvant Treatment of HER2+ Breast Cancer
William J. Gradishar, MD, and Joyce O’Shaughnessy, MD, discuss the challenges related to the use of lapatinib in the neoadjuvant setting.
Predicting Response/Resistance to HER2-Targeted Therapies in the Neoadjuvant Setting
William J. Gradishar, MD, and Joyce O’Shaughnessy, MD, discuss patient factors that predict the likelihood of response to HER2-targeted therapies in the neoadjuvant therapies.
AC-THP Versus TCHP Treatment
Joyce O’Shaughnessy, MD, Claudine Isaacs, MD, and Hope S. Rugo, MD, discuss the use of AC-THP compared with TCHP in women with breast cancer.
